Before revision: Bioinformatics of high throughput omics data (e. g. microarrays and proteomics) has been plagued by uncountable issues with reproducibility at the start of the century. Concerns have motivated international initiatives such as the FDA's led MAQC Consortium , addressing reproducibility of predictive biomarkers by means of appropriate Data Analysis Plans (DAPs) .
After revision: Reproducibility of AI models on biomedical data still stays as a major concern for their acceptance into the clinical practice. Initiatives for reproducibility in the development of predictive biomarkers as the MAQC Consortium already underlined the importance of appropriate Data Analysis Plans (DAPs) .